Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study)Research in context

• Hauptverfasser: Pascal Demoly (VerfasserIn), Mathieu Molimard (VerfasserIn), Jean-François Bergmann (VerfasserIn), Bertrand Delaisi (VerfasserIn), Amandine Gouverneur (VerfasserIn), Jade Vadel (VerfasserIn), Cédric Collin (VerfasserIn), Laurence Girard (VerfasserIn), Silvia Scurati (VerfasserIn), Philippe Devillier (VerfasserIn)
• Format: Buch
• Veröffentlicht: Elsevier, 2024-06-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Summary: Background: The only disease-modifying treatment currently available for allergic rhinitis (AR) is allergen immunotherapy (AIT). The main objective of the EfficAPSI real-world study (RWS) was to evaluate the impact of liquid sublingual immunotherapy (SLIT-liquid) on asthma onset and evoluti...